Related Experiment Video
Updated: Oct 2, 2025
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
A Second-Generation Nanoluc-IL27 Fusion Cytokine for Targeted-Gene-Therapy Applications
Janelle Wesleyn Salameh1,2, Shreya Kumar1, Cosette Marie Rivera-Cruz1
1The Department of Basic Medical Sciences, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Abstract:
An emerging approach in treating skeletal malignancies utilizes osteoimmunology to investigate new multifunctional immune-stimulatory agents that can simultaneously combat tumor growth and promote bone repair. We have hypothesized that cytokine Interleukin-27 (IL-27) is an excellent candidate biologic to help rebalance the prostate tumor cells and bone cell environment. In this work, we examined the proof of principle for a short, secreted luciferase (Nanoluc or Nluc) fusion with IL-27 to produce a novel cytokine-based biologic (Nluc-27), whereby we examined its efficacy in vitro in reducing prostate tumor growth and rebalancing bone cell proliferation and differentiation. This work demonstrates the targeting and anti-tumor efficacy of the Nluc-27 fusion cytokine in cancer and bone cell models. The fusion cytokine is detectable in conditioned media, and bioactive in different cell systems. This novel Nluc-27 cytokine will allow flexible incorporation of other targeting domains and may serve as flexible tool to augment IL-27's bioactivity and reengineer its efficacy against prostate tumor or bone cells, and may prove applicable to several other cell types for targeted gene therapy applications.
Insights
Researchers developed a novel fusion cytokine, Nanoluciferase-Interleukin-27 (Nluc-27), to target prostate tumors and promote bone repair. This biologic shows promise in combating cancer and rebalancing bone cells.
Area of Science:
- Osteoimmunology
- Molecular Biology
- Biotechnology
Background:
- Skeletal malignancies present complex treatment challenges requiring agents that target tumors and support bone regeneration.
- Interleukin-27 (IL-27) is a cytokine with potential to modulate the tumor microenvironment and bone cell activity.
Purpose of the Study:
- To develop and evaluate a novel fusion biologic, Nanoluciferase-Interleukin-27 (Nluc-27), for treating prostate cancer and associated bone abnormalities.
- To assess the in vitro efficacy of Nluc-27 in reducing prostate tumor growth and rebalancing bone cell proliferation and differentiation.
Main Methods:
- Construction of a fusion protein combining Nanoluciferase (Nluc) with Interleukin-27 (IL-27).
- In vitro assessment of Nluc-27 bioactivity, detectability in conditioned media, and anti-tumor efficacy in prostate cancer models.
- Evaluation of Nluc-27's impact on bone cell proliferation and differentiation.
Main Results:
- The Nluc-27 fusion cytokine was successfully produced and detected in conditioned media.
- Nluc-27 demonstrated anti-tumor efficacy against prostate cancer cells in vitro.
- The fusion cytokine showed bioactivity in various cell systems, influencing bone cell behavior.
Conclusions:
- The novel Nluc-27 fusion cytokine is a viable biologic agent for targeting prostate tumor cells and modulating the bone microenvironment.
- Nluc-27 offers a flexible platform for enhancing IL-27's bioactivity and can be adapted for targeted gene therapy in various cell types.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
00:59Gene Therapy